Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model

Area of Science:

• Oncology
• Immunotherapy
• Radiotherapy

Background:

• Cancer therapeutic vaccines and radiation therapy have over a century of research, with largely untapped potential.
• Established therapies include antiangiogenics, nanoparticle targeting, and immune modulators, while immunotherapy gains clinical traction.

Purpose of the Study:

• To propose a novel pulsed/intermittent/cyclical endothelial-sparing single-dose in situ vaccination (ISVRT) schedule.
• To differentiate ISVRT from standard stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) plans.
• To explore ISVRT's potential for generating tumor-specific neoantigens and immune modulation.

Main Methods:

• The proposed ISVRT schedule focuses on optimizing cascading antigenicity and adjuvanticity.
• A validation algorithm is presented for the ISVRT hypothesis.
• The approach integrates immunotherapy, targeted therapy, chemotherapy, antiangiogenics, and vascular-lymphatic normalization.

Main Results:

• ISVRT aims to repeatedly generate tumor-specific neoantigens and epitopes.
• Potential benefits include augmented immune enhancement, activation of long-term memory cells, and avoidance of extracellular matrix fibrosis.
• The schedule is designed to synchronize with the vascular normalized immunity cycle.

Conclusions:

• ISVRT offers a new paradigm for treating locally progressing or metastatic cancers that have not responded to standard therapies.
• This approach leverages in situ vaccination principles to enhance anti-tumor immunity.
• The proposed ISVRT strategy holds promise for optimizing cancer treatment outcomes through combined immunomodulatory and vascular-targeting mechanisms.